{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:40Z","timestamp":1792039600506,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109632","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:35:02Z","timestamp":1790033702000},"page":"109632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Time-dependent impact of programmed death-ligand 1 expression on early progression and long-term response to first-line osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-5878","authenticated-orcid":false,"given":"Toshiyuki","family":"Sumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4016-7335","authenticated-orcid":false,"given":"Yutaro","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuru","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5306-4045","authenticated-orcid":false,"given":"Masami","family":"Yamazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiki","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Koshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Shioya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2565-5300","authenticated-orcid":false,"given":"Kanami","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-9344","authenticated-orcid":false,"given":"Hirotaka","family":"Nishikiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-3084","authenticated-orcid":false,"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109632_b0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"FLAURA Investigators, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109632_b0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"FLAURA Investigators, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109632_b0015","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"FLAURA2 Investigators, Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109632_b0020","doi-asserted-by":"crossref","unstructured":"P.A. J\u00e4nne, D. Planchard, K. Kobayashi, J.C.H. Yang, Y. Liu, N. Valdiviezo, T.M. Kim, L. Jiang, H. Kagamu, N. Yanagitani, J. Wang, B. Biswas, A. Poltoratskiy, Y. Neron, C. Rojas, L. Koubkova, C. Escriu, D.A. Ezeife, H. Mann, E. Armenteros-Monterroso, Y. Rukazenkov, C.K. Lee, FLAURA2 Investigators, Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC, N. Engl. J. Med. Published online October 17, 2025. 394 (2025) 27\u201338. 10.1056\/NEJMoa2510308.","DOI":"10.1056\/NEJMoa2510308"},{"key":"10.1016\/j.lungcan.2026.109632_b0025","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109632_b0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109632_b0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.lungcan.2026.109632_b0040","doi-asserted-by":"crossref","first-page":"9753","DOI":"10.1038\/s41598-022-13102-7","article-title":"PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment na\u00efve advanced EGFR-mutant non-small cell lung cancer patients","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2026.109632_b0045","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.21873\/anticanres.15736","article-title":"Prognostic implication of PD-L1 expression on osimertinib treatment for EGFR-mutated non-small cell lung cancer","volume":"42","author":"Shiozawa","year":"2022","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2026.109632_b0050","first-page":"2165","article-title":"FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression, Transl. Lung","volume":"9","author":"Abdayem","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109632_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100369","article-title":"Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors","volume":"29","author":"Chen","year":"2021","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.lungcan.2026.109632_b0060","doi-asserted-by":"crossref","first-page":"e7152","DOI":"10.1002\/cam4.7152","article-title":"Assessing EGFR-mutated NSCLC with bone metastasis: clinical features and optimal treatment strategy","volume":"13","author":"Chen","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2026.109632_b0065","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241303090","article-title":"Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with EGFR-mutated non-small-cell lung cancer: a retrospective, multicenter cohort study","volume":"16","author":"Tanaka","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109632_b0070","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.2147\/CMAR.S207170","article-title":"Impact of EGFRgenotype on the efficacy of osimertinib in EGFRtyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study","volume":"11","author":"Igawa","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lungcan.2026.109632_b0075","article-title":"Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLOS One."},{"key":"10.1016\/j.lungcan.2026.109632_b0080","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"TRACERx Consortium, Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109632_b0085","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","article-title":"Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation\u2013positive non\u2013small cell lung cancer","volume":"26","author":"Isomoto","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109632_b0090","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2026.109632_b0095","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109632_b0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/imt-2019-0213","article-title":"Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy","volume":"12","author":"Matsumoto","year":"2020","journal-title":"Immunotherapy."},{"key":"10.1016\/j.lungcan.2026.109632_b0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","article-title":"Bone marrow niches in haematological malignancies","volume":"20","author":"M\u00e9ndez-Ferrer","year":"2020","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.lungcan.2026.109632_b0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2015.04.007","article-title":"The incidence and clinical impact of bone metastases in non-small cell lung cancer","volume":"89","author":"Kuchuk","year":"2015","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109632_b0115","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature."},{"key":"10.1016\/j.lungcan.2026.109632_b0120","article-title":"Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis","volume":"211","author":"Alexander","year":"2025","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109632_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108808","article-title":"Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib","volume":"210","author":"Chen","year":"2025","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109632_b0130","doi-asserted-by":"crossref","unstructured":"A. Mouri, K. Kaira, O. Yamaguchi, A. Shiono, Y. Miura, K. Hashimoto, S. Yamasaki, F. Nishihara, H. Imai, K. Kobayashi, H. Kagamu, Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations, Cancer Immunol. Immunother. 74: epub ahead of print (2025) 265. doi.org\/10.1007\/s00262-025-04113-0, https:\/\/pubmed.ncbi.nlm.nih.gov\/40650761\/.","DOI":"10.1007\/s00262-025-04113-0"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109632_b0135","article-title":"The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)","volume":"5","author":"Watanabe","year":"2024","journal-title":"JTO Clin Res Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:08:33Z","timestamp":1792037313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":27,"alternative-id":["S0169500226006938"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109632","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time-dependent impact of programmed death-ligand 1 expression on early progression and long-term response to first-line osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109632"}}